The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Dec. 08, 2020
Filed:
Feb. 04, 2016
Applicant:
Navigo Proteins Gmbh, Halle/Saale, DE;
Inventors:
Eva Bosse-Doenecke, Halle/Saale, DE;
Florian Settele, Halle/Saale, DE;
Erik Fiedler, Halle/Saale, DE;
Ulrich Haupts, Halle/Saale, DE;
Assignee:
Navigo Proteins GmbH, Halle/Saale, DE;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 14/435 (2006.01); C07K 14/71 (2006.01); C07K 14/00 (2006.01); C07K 16/28 (2006.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
C07K 14/435 (2013.01); C07K 14/00 (2013.01); C07K 14/71 (2013.01); C07K 16/2863 (2013.01); A61K 38/00 (2013.01); C07K 2317/24 (2013.01); C07K 2317/92 (2013.01); C07K 2319/30 (2013.01); C07K 2319/31 (2013.01); C07K 2319/95 (2013.01);
Abstract
The present invention relates to new EGFR binding molecules based on ubiquitin muteins (Affilin®), preferably Affilin molecules having a characteristic three amino acid residue motif. The invention further refers to EGFR binding molecules that bind to different or non-overlapping epitopes than the anti-EGFR monoclonal antibody Cetuximab. The invention further relates to the use of these EGFR binding proteins in medicine, preferably for use in the diagnosis or treatment of cancer.